Table 7.

Overview of the adverse event (AE) profile in the population used for safety assessments

	IqYmune® N = 22	Kiovig® N = 21
Any AE	83 (16; 72.7%)	78 (15; 71.4%)
Serious AEs	0	0
All drug‐related AEs	39 (10; 45.5%)	32 (11; 52.4%)
Drug‐related AEs occurring in at least two participants with either product
Headache	14 (6; 27.3%)	14 (9; 42.9%)
Neutropenia	3 (1; 4.5%)	5 (1; 4.8%)
Pruritus	6 (1; 4.5%)	0
Fatigue	3 (2; 9.1%)	1 (1; 4.8%)
Leukopenia	1 (1; 4.5%)	3 (1; 4.8%)
Nausea	2 (2; 9.1%)	1 (1; 4.8%)
Vomiting	2 (1; 4.5%)	1 (1; 4.8%)

The data shown are the numbers of AEs occurring (number and percentage of participants).